The stock has a 36-month beta value of 1.32. Opinions on the stock are mixed, with 15 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for DNLI is 125.78M, and at present, short sellers hold a 9.62% of that float. On June 04, 2025, the average trading volume of DNLI was 1.49M shares.
DNLI) stock’s latest price update
The stock of Denali Therapeutics Inc (NASDAQ: DNLI) has decreased by -0.21 when compared to last closing price of 13.96. Despite this, the company has experienced a 5.45% gain in its stock price over the last five trading sessions. zacks.com reported 2025-05-07 that DNLI reports a wider-than-expected loss for the first quarter of 2025. Denali submits a BLA for tividenofusp alfa under the FDA?
DNLI’s Market Performance
DNLI’s stock has risen by 5.45% in the past week, with a monthly drop of -15.27% and a quarterly drop of -12.66%. The volatility ratio for the week is 3.48% while the volatility levels for the last 30 days are 3.96% for Denali Therapeutics Inc The simple moving average for the past 20 days is 0.24% for DNLI’s stock, with a -34.64% simple moving average for the past 200 days.
Analysts’ Opinion of DNLI
Morgan Stanley, on the other hand, stated in their research note that they expect to see DNLI reach a price target of $33, previously predicting the price at $41. The rating they have provided for DNLI stocks is “Overweight” according to the report published on March 07th, 2025.
Deutsche Bank gave a rating of “Buy” to DNLI, setting the target price at $31 in the report published on February 11th of the current year.
DNLI Trading at -0.26% from the 50-Day Moving Average
After a stumble in the market that brought DNLI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.21% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DNLI starting from Ho Carole, who sale 12,255 shares at the price of $20.22 back on Jan 06 ’25. After this action, Ho Carole now owns 178,580 shares of Denali Therapeutics Inc, valued at $247,796 using the latest closing price.
Ho Carole, the Chief Medical Officer of Denali Therapeutics Inc, sale 2,907 shares at $20.81 during a trade that took place back on Jan 07 ’25, which means that Ho Carole is holding 175,673 shares at $60,495 based on the most recent closing price.
Stock Fundamentals for DNLI
The total capital return value is set at -0.44. Equity return is now at value -35.21, with -31.83 for asset returns.
Based on Denali Therapeutics Inc (DNLI), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -7.52.
Currently, EBITDA for the company is -414.91 million with net debt to EBITDA at 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.56.
Conclusion
To sum up, Denali Therapeutics Inc (DNLI) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
